$75.7B of 2025 immunology blockbuster sales lose US exclusivity by 2037, led by Dupixent, Skyrizi, Rinvoq. These 19 public biotechs have 44 immunology treatments in Phase 3 or filed with the FDA, 10 of them already filed.
2025 sales each company reports from tracked immunology treatments losing US exclusivity by 2037. Big pharma has spent $53.6B on 11 immunology acquisitions since 2023. See the deals →
Oral TYK2 inhibitor files for psoriasis on clean Phase 3 data, but LUMUS miss narrows the franchise story to one approved indication
First-ever approved dermatomyositis therapy just launched; commercial uptake now determines whether a multi-indication TYK2/JAK1 platform compounds or stalls
Single-arm BLA for a CAR-T that erases myositis in small cohorts: does FDA accept the data without a randomized control?
Dual Phase 3 wins in HS and PsA position sonelokimab for multi-indication filing; BLA acceptance and label scope are the make-or-break conditions
Lumvoa approved and launched in TED; elegrobart Phase 3 wins set up a second BLA; commercial execution against Tepezza is now the deciding test
Anaphylm resubmitted after fixing every CRL deficiency; FDA classification and review clock are the remaining gating items
Medicare coverage unlocked, FDA clearance pending; GraftAssure's commercial future depends on authorization before cash runs out
Ionis has three approved drugs and two fresh Phase 3 wins, but the hepatitis B functional-cure PDUFA is the single event that rerates the stock
Outpatient mRNA CAR-T skips lymphodepletion entirely; Phase 3 AURORA tests whether that tolerability comes at the cost of efficacy in MG
IMVT-1402 runs five autoimmune trials after batoclimab's collapse; RA and MG registrational readouts determine platform survival
Regulatory T-cell biology meets a crowded atopic dermatitis field: Phase 3 data in mid-2028 determines whether rezpegaldesleukin earns a place among established biologics
Positive Phase 3 efficacy and funding support obefazimod's NDA, with FDA review and labeling now the central tests
Allogeneic NK cell therapy for refractory RA shows 71% ACR50 in small Phase 2a cohort; Phase 3 RCT will prove or disprove whether outpatient B-cell reset scales
Phase 2 HS win and $472M war chest position abdakibart for Phase 3, contingent on replicating that signal at registrational scale
Biohaven pivots to BHV-1300 in Graves' disease after troriluzole CRL and OCD failure, with a $795M Kv7 licensing deal buying time for a 2027 Phase 3 readout
Tacrolimus challenger with cleaner safety profile heads into Phase 3, but runway expires well before trial data arrives
Rolling miv-cel BLA underway in stiff person syndrome; FDA's view of single-arm data remains decisive
Ryoncil's $115M launch year funds the rexlemestrocel-L CLBP Phase 3 bet; the readout determines whether Mesoblast is a commercial platform or a one-product story
BRIUMVI nearing $1B annual revenue with SC formulation and indication expansions as the growth ceiling test
Filed treatments are listed first. This shows where late-stage treatments are being developed, not which companies will be acquired. Pipeline data and summaries from Readouts as of 29 September 2026; companies already acquired are left out.
Other areas: Oncology · Cardiometabolic · Vaccine · Infectious disease · Neuroscience · Other areas